Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Kymera Therapeutics ( (KYMR) ) has provided an update.
On January 14, 2025, Kymera Therapeutics announced its 2025 objectives and strategy, focusing on advancing its immunology programs, particularly the investigational oral degrader KT-621. The company is conducting a Phase 1 trial for KT-621, with plans to move into Phase 1b and 2b trials by late 2025 and early 2026, targeting conditions like atopic dermatitis and asthma. Kymera is also set to introduce a novel oral immunology program in the first half of 2025. The announcements highlight the company’s commitment to expanding its pipeline and leveraging targeted protein degradation to offer biologics-like oral therapies, positioning itself as a leader in the field.
More about Kymera Therapeutics
Kymera Therapeutics is a clinical-stage biotechnology company specializing in targeted protein degradation to create oral small molecule degrader medicines for immunological diseases. Founded in 2016, the company aims to address disease targets and pathways that are unreachable with conventional therapeutics, establishing an industry-leading pipeline in the process.
YTD Price Performance: -8.98%
Average Trading Volume: 445,720
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $2.47B
For a thorough assessment of KYMR stock, go to TipRanks’ Stock Analysis page.
